Paris-based Sanofi has acquired Waltham, Mass.-based Bioverativ for about $11.6 billion.
Biotech deal activity exploded with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products to their medicine cabinets.
PALIO will fuse with GSW to deliver customers the best of both agencies’ integrated advertising and marketing solutions.
In this newly created role, Jennifer Gottlieb is responsible for three operating companies – W2O wcg, W2O twist and W2O pure.
Teva Pharmaceutical Industries said two late-stage studies testing the company’s treatment for asthma did not meet their main goals.
The U.S. FDA granted Priority Review to daratumumab as a combination treatment for patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant.
A sound-emitting device worn in the ear during sleep may train the brain to ignore an annoying chronic ringing in the ears, a new study suggests.
In this white paper, PMC contends that most value assessment frameworks could unintentionally undermine the health care community’s push toward more personalized care.
Biotech investing is a volatile business as 2018 has seen a little-known hedge fund with a focus on biotech and the life sciences beat out a couple of heavy hitters, David Einhorn and Bill Ackman.
Cuts implemented by Israel-based Teva Pharmaceutical hit the shores of the United States. The company is laying off 208 people in the Philadelphia area.
Pharma giant AstraZeneca has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reuters reported.
The HHS is issuing new regulations aimed at protecting healthcare workers’ civil rights based on religious and conscience objections.
AstraZeneca and Merck announced that the Japanese Ministry of Health, Labour and Welfare approved Lynparza (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded to their last platinum-based chemotherapy.
The FDA head is preparing a new, more restrictive policy targeting which drugs compounding pharmacies can produce that do not go through the regulatory agency’s approval process.
Amgen Inc. and Allergan plc. announced that the European Commission granted marketing authorization for Mvasi (biosimilar bevacizumab).
Fresh off its $7 billion acquisition of San Diego-based Impact Biomedicines and its JAK inhibitor program targeting myelofibrosis, Celgene is planning to open a biopharma incubator on its corporate campus in New Jersey.
The U.S. Department of Veterans Affairs and Intermountain Healthcare, Ascension, SSM Health and Trinity Health are forming a not-for-profit generic drug company.
Backed by financing from a collaboration with Novartis and an $83 million financing round, Homology Medicines is moving to a new facility with more than triple the space of its headquarters.
Research carried out in part by an artificially intelligent ‘robot scientist’ found that a common ingredient of toothpaste could be developed to fight drug-resistant strains of malaria.
A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions.